All patients
age >= 55 yr age >= 65 yr critical disease omicron variant BA.1 (B.1.1.529) solid organ transplant recipients subjects at risk
Immunostimulants drugs in COVID 19 outpatients - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias Emergency room visit or hospitalizationdetailed results TOGETHER interferon lambda, 2022 0.47 [0.29; 0.77]
0.47 [0.29 ; 0.77 ] TOGETHER interferon lambda, 2022 1 0% 1,936 NA not evaluable death D28detailed results C3PO, 2020 5.02 [0.58; 43.27]
COMET-ICE, 2021 0.25 [0.01; 5.55]
CoV-Early (Gharbharan), 2022 1.01 [0.06; 16.25]
CT-P59 3.2 part 2, 2021 0.50 [0.05; 5.54]
TOGETHER interferon lambda, 2022 0.28 [0.03; 2.49]
0.80 [0.25 ; 2.53 ] C3PO, 2020, COMET-ICE, 2021, CoV-Early (Gharbharan), 2022, CT-P59 3.2 part 2, 2021, TOGETHER interferon lambda, 2022 5 9% 5,235 low not evaluable deathsdetailed results ACTIV-2 (BRII-196 and BRII-198), 0 0.05 [0.00; 0.94]
BLAZE-1 phase 3 (combo), 2021 0.05 [0.00; 0.84]
C3PO, 2020 5.02 [0.58; 43.27]
COMET-ICE, 2021 0.25 [0.01; 5.55]
CONV-ERT, 2021 0.20 [0.01; 4.07]
Cov-2067 Weinreich (1200mg) Cohort 1, 2020 0.45 [0.05; 3.82]
Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 1.01 [0.02; 51.05]
CoV-Early (Gharbharan), 2022 1.01 [0.06; 16.25]
TOGETHER interferon lambda, 2022 0.28 [0.03; 2.49]
0.39 [0.14 ; 1.08 ] ACTIV-2 (BRII-196 and BRII-198), 0, BLAZE-1 phase 3 (combo), 2021, C3PO, 2020, COMET-ICE, 2021, CONV-ERT, 2021, Cov-2067 Weinreich (1200mg) Cohort 1, 2020, Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021, CoV-Early (Gharbharan), 2022, TOGETHER interferon lambda, 2022 9 22% 9,121 low not evaluable hospitalization or deathdetailed results ACTIV-2 (BRII-196 and BRII-198), 0 0.22 [0.05; 0.91]
BLAZE-1 phase 2 (combination with etesevimab), 2020 0.15 [0.02; 1.18]
BLAZE-1 phase 2 (monotherapy), 2020 0.16 [0.02; 1.31]
BLAZE-1 phase 3 (combo), 2021 0.29 [0.15; 0.58]
C3PO, 2020 0.91 [0.63; 1.33]
COMET-ICE, 2021 0.21 [0.09; 0.49]
Cov-2067 Weinreich (1200mg) Cohort 1, 2020 0.29 [0.12; 0.68]
CT-P59 3.2 part 1, 2021 0.48 [0.19; 1.25]
CT-P59 3.2 part 2, 2021 0.29 [0.16; 0.51]
TACKLE, 0 0.47 [0.26; 0.84]
0.36 [0.23 ; 0.55 ] ACTIV-2 (BRII-196 and BRII-198), 0, BLAZE-1 phase 2 (combination with etesevimab), 2020, BLAZE-1 phase 2 (monotherapy), 2020, BLAZE-1 phase 3 (combo), 2021, C3PO, 2020, COMET-ICE, 2021, Cov-2067 Weinreich (1200mg) Cohort 1, 2020, CT-P59 3.2 part 1, 2021, CT-P59 3.2 part 2, 2021, TACKLE, 0 10 64% 7,056 low critical clinical deteriorationdetailed results COMET-ICE, 2021 0.24 [0.10; 0.56]
0.24 [0.10 ; 0.56 ] COMET-ICE, 2021 1 0% 1,057 NA not evaluable clinical improvement (time to event analysis only)detailed results CT-P59 3.2 part 2, 2021 1.50 [1.30; 1.74]
1.50 [1.30 ; 1.74 ] CT-P59 3.2 part 2, 2021 1 0% 1,315 NA not evaluable hospitalizationdetailed results C3PO, 2020 0.88 [0.57; 1.34]
COMET-ICE, 2021 0.20 [0.08; 0.48]
CONV-ERT, 2021 1.05 [0.78; 1.41]
Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 0.08 [0.00; 1.49]
CoV-Early (Gharbharan), 2022 0.61 [0.28; 1.33]
TOGETHER interferon lambda, 2022 0.56 [0.33; 0.96]
0.61 [0.38 ; 0.97 ] C3PO, 2020, COMET-ICE, 2021, CONV-ERT, 2021, Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021, CoV-Early (Gharbharan), 2022, TOGETHER interferon lambda, 2022 6 71% 4,472 low serious mechanical ventilationdetailed results C3PO, 2020 1.49 [0.25; 9.02]
1.49 [0.25 ; 9.02 ] C3PO, 2020 1 0% 498 NA not evaluable Recovery (time to event analysis only)detailed results CT-P59 3.2 part 2, 2021 1.50 [1.30; 1.74]
1.50 [1.30 ; 1.74 ] CT-P59 3.2 part 2, 2021 1 0% 1,315 NA not evaluable symptomatic Covid-19detailed results Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 0.56 [0.31; 1.00]
0.56 [0.31 ; 1.00 ] Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 1 0% 204 NA not evaluable viral clearance detailed results BLAZE-1 phase 2 (combination with etesevimab), 2020 1.65 [0.91; 3.00]
BLAZE-1 phase 2 (monotherapy), 2020 0.67 [0.33; 1.38]
1.08 [0.45 ; 2.60 ] BLAZE-1 phase 2 (combination with etesevimab), 2020, BLAZE-1 phase 2 (monotherapy), 2020 2 72% 470 moderate not evaluable viral clearance by day 7detailed results BLAZE-1 phase 2 (combination with etesevimab), 2020 1.31 [0.61; 2.83]
BLAZE-1 phase 2 (monotherapy), 2020 0.91 [0.39; 2.09]
BLAZE-4, 0 0.37 [0.20; 0.66]
Feld, 2021 4.12 [1.08; 15.71]
1.03 [0.42 ; 2.52 ] BLAZE-1 phase 2 (combination with etesevimab), 2020, BLAZE-1 phase 2 (monotherapy), 2020, BLAZE-4, 0, Feld, 2021 4 79% 831 low not evaluable emergent treatment-resistant variantsdetailed results BLAZE-1 phase 2 (combination with etesevimab), 2020 0.18 [0.02; 1.51]
BLAZE-1 phase 2 (monotherapy), 2020 1.52 [0.51; 4.47]
0.64 [0.08 ; 4.94 ] BLAZE-1 phase 2 (combination with etesevimab), 2020, BLAZE-1 phase 2 (monotherapy), 2020 2 67% 497 moderate not evaluable serious adverse eventsdetailed results Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 0.25 [0.03; 2.23]
0.25 [0.03 ; 2.23 ] Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 1 0% 311 NA not evaluable adverse eventsdetailed results COMET-ICE, 2021 0.91 [0.68; 1.22]
Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 0.55 [0.34; 0.86]
0.73 [0.44 ; 1.20 ] COMET-ICE, 2021, Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 2 71% 1,360 low not evaluable 0.0 2.0 1.0 relative treatment effect www.metaEvidence.org 2024-04-28 09:30 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 97
- treatments: 597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567
- roots T: 290
